EFFECT OF COMPLEX TREATMENT USING PLATELET AUTOPLASMA ON CLINICAL AND LABORATORY PARAMETERS OF PATIENTS WITH ENDOGENOUS UVEITIS AND MACULAR EDEMA

Purpose: to study the clinical and laboratory efficacy of the platelet autoplasma use in the complex treatment of endogenous uveitis associated with systemic diseases accompanied by macular edema. Material and methods. The study included 46 people (72 eyes) with endogenous uveitis and macular edema. The diagnosis was made on the basis of the ophthalmological examination, including visometry, tonometry, biomicroscopy, ophthalmoscopy, perimetry, B-scan, optical coherence tomography of the macular zone, photoregistration of the anterior, posterior segment of the eye. The examination was carried out on the 1st and 10th day of treatment. The main group consisted of 22 people (36 eyes) who underwent anti-inflammatory therapy and the introduction of platelet plasma in the region of the pterygopalatine fossa. The control group consisted of 24 people (36 eyes) receiving only anti-inflammatory therapy (diprospan 0.5 paraequatorially №1, dexazone 4 mg intravenously №5, intravenous lasix 2.0 ml №5, electrophoresis with prednisolone № 7). All patients underwent the definition of IL-4, IL-6, IL-8, IL-17 in tear fluid before the study and on the 10th day. Results. The significant increase in the concentrations of pro-inflammatory cytokines (IL-17A and IL-8) and IL-4 and IL-6 involved in the development of autoimmune response and chronic inflammation was found in the patients with endogenous uveitis and macular edema. The use in the treatment of endogenous uveitis with macular edema of platelet autoplasma leads to more pronounced improvement of clinico-ophthalmological parameters (improvement in visual acuity, retinal photosensitivity, and retinal thickness reduction) relating to the comparison group. A decrease in the activity of the inflammatory process was noted in the main group after treatment, which is manifested by a significant decrease in the concentrations of IL-17A, IL-8, IL-4, IL-6, relating to the data obtained in the comparison group. The proposed scheme of complex treatment allows reducing the frequency of relapses of the pathological process.

1. Arbeneva N.S., Chekhova T.A., Bratko V.I., Trunov A.N., Chernykh V.V. A retrospective analysis of the structure of uveitis (according to the data of the Novosibirsk branch of the MNTK «Eye Microsurgery»). Prakticheskaya meditsina = Practical Medicine. 2017; 2 (9): 25–28. [In Russian].

2. Achkasov E.E., Bezuglov E.N., Ulyanov A.A., Kurshev V.V., Repetyuk A.D., Egorova O.N. Application of autoplasma enriched with platelets in clinical practice. Biomeditsina = Biomedicine. 2013; (4): 46–59. [In Russian].

3. Bratko V.I., Chekhova T.A., Kulakov A.V., Arbeneva N.S., Chernykh V.V., Trunov A.N. The method of complex treatment of endogenous uveitis, accompanied by macular edema. Patent 2635083 RF; Published 11.08.2017. [In Russian].

4. Drozdova E.A. The classification and epidemiology of uveitis. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2016; (3): 155–159. [In Russian].

5. Dubinina T.V., Demina A.B., Erdes Sh.F. HLA-B27-associated uveitis: epidemiology, clinical picture and complications. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2014; (3): 304–310. [In Russian].

6. Lykov A.P., Surovtseva M.A., Poveshchenko O.V., Stanishevskaya O.M., Chernykh D.V., Arbeneva N.S., Bratko V.I. Treatment of idiopathic age-related macular degeneration with autologous plasma enriched with platelet lysate: prospective study. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2018; 73 (1): 40–48.

7. Trunov A.N., Arbeneva N.S., Shvayuk A.P., Gorbenko O.M., Obukhova O.O. Imbalance of cytokines in the tear fluid of patients with autoimmune uveitis. Vestnik Orenburgskogo gosudarstvennogo universiteta = Bulletin of the Orenburg State University. 2013; (4): 270–274. [In Russian].

8. Anitua E., Muruzabal F., de la Fuente M., Merayo-Lloves J., Orive G. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp. Eye Res. 2014; 119: 27–34.

9. Anitua E., Muruzabal F., Tayebba A., Riestra A., Perez V.L., Merayo-Lloves J., Orive G. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015; 93 (8): 605–614.

10. Bin Ismail M.A., Lim R.H., Fang H.M., Wong E.P., Ling H.S., Lim W.K., Teoh S.C., Agrawal R. Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS)-report 4: analysis and outcome of scleritis in an East Asian population. J. Ophthalmic Inflamm. Infect. 2017; 7 (1): 6.

11. Çakar Özdal M.P., Yazici A., Tüfek M., Öztürk F. Epidemiology of uveitis in a referral hospital in Turkey. Turk. J. Med. Sci. 2014; 44 (2): 337–342.

12. Carreño E., Portero A., Herreras J.M., García-Vázquez C., Whitcup S.M., Stern M.E., Calonge M., Enríquez-de-Salamanca A. Cytokine and chemokine tear levels in patients with uveitis. Acta Ophthalmol. 2017; 95 (5): 405–414.

13. Chen E.J., Bin Ismail M.A., Mi H., Ho S.L., Lim W.K., Teoh S.C., Agrawal R. Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) – Report 1: Epidemiology and classification. Ocul. Immunol. Inflamm. 2016; 6 (5): 1–15.

14. Fardeau C., Champion E., Massamba N. Uveitic macular edema. Eye (Lond). 2016; 30 (10): 1277–1292.

15. Guedes M., Borrego L.M., Proença R.D. Roles of interleukin-17 in uveitis. Indian J. Ophthalmol. 2016; 64 (9): 628–634.

16. Gutteridge I.F., Hall A.J. Acute anterior uveitis in primary care. Clin. Exp. Optom. 2007; 90 (2): 70–82.

17. Jabs D.A., Busingye J. Approach to the diagnosis of the uveitides. Am. J. Ophthalmol. 2013; 156 (2): 228–236.

18. Kim K.M., Shin Y.T., Kim H.K. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn. J. Ophthalmol. 2012; 56 (6): 544–550.

19. Konstantinidis A., Hero M., Nanos P., Panos G.D. Efficacy of autologous platelets in macular hole surgery. Clin. Ophthalmol. 2013; (7): 745–750.

20. Kozak I., Shoughy S.S., Stone D.U. Intravitreal antiangiogenic therapy of uveitic macular edema: A review. J. Ocul. Pharmacol. Ther. 2017; 33 (4): 235–239.

21. Lee R.W., Nicholson L.B., Sen H.N., Chan C.C., Wei L., Nussenblatt R.B., Dick A.D. Autoimmune and autoinflammatory mechanisms in uveitis. Semin. Immunopathol. 2014; 36 (5): 581–594.

22. Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015; 11 (9): 1697–1702.

23. Miserocchi E., Fogliato G., Modorati G., Bandello F. Review on the worldwide epidemiology of uveitis. Eur. J. Ophthalmol. 2013; 23 (5): 705–717.

24. Mitkova-Hristova V.T., Konareva-Kostianeva M.I. Macular edema in uveitis. Folia Med. (Plovdiv). 2012; 54 (3): 14–21.

25. Paroli M.P. Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence thomography study. Ocular Immunol. Inflam. 2010; 18 (1): 54–59.

26. Prete M., Dammacco R., Fatone M.C., Racanelli V. Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. Clin. Exp. Med. 2016; 16 (2): 125–136.

27. Ronci C., Ferraro A.S., Lanti A., Missiroli F., Sinopoli S., del Proposto G., Cipriani C., de Felici С., Ricci F., Ciotti M., Cudillo L., Arcese W., Adorno G. Platelet-rich plasma as treatment for persistent ocular epithelial defects. Transfus. Apher. Sci. 2015; 52 (3): 300–304.

28. Sun D., Liang D., Kaplan H.J., Shao H. The role of Th17-associated cytokines in the pathogenesis of experimental autoimmune uveitis (EAU). Cytokine. 2015; 74 (1): 76–80.

29. Thorne J.E., Suhler E., Skup M., Tari S., Macaulay D., Chao J., Ganguli A. Prevalence of noninfectious uveitis in the United States: A claims-based analysis. JAMA Ophthalmol. 2016; 134 (11): 1237–1245.

30. Trusko B., Thorne J., Jabs D., Belfort R., Dick A., Gangaputra S., Nussenblatt R., Okada A., Rosenbaum J. The Standardization of Uveitis Nomenclature (SUN) Project. Development of clinical evidence base utilizing informatics tools and techniques. Methods Inf. Med. 2013; 52 (3): 259–265.